The Pharmaceutical Industry's Approach To AIDS As A Global Market

  1. In the following paragraphs I address the business strategy behind the promotion of toxic ARVs – as AIDS chemotherapy – by the pharmaceutical industry. In brief, the pharmaceutical response to AIDS is to treat this epidemic as a global market and a multibillion-billion Rand opportunity to increase its return on investments in patented ARV drugs.
  2. ARVs are the most common pharmaceutical approaches to AIDS. Most ARVs are derivatives of drugs used in the “chemotherapy” of cancer. The underlying therapeutic mechanism of these drugs is to damage or destroy the cells of the body in the hope to also impair or destroy cancer cells or – in the case of AIDS – virus containing cells.
  3. It is basic knowledge that the primary target organ of these toxic chemotherapeutic drugs is the bone marrow in the human body. Moreover, the first cells toxically damaged are the fastest reproducing cells, i.e. the blood cells deriving from the bone marrow. This inevitably leads to the impaired production and function of almost all subtypes of white blood cells and other cells that determine immune function in the body.
  4. AIDS, the acquired immune deficiency syndrome, is by definition an immune deficiency condition – i.e. a disease characterized by an impaired function of the immune system. A 13-year old understands that a toxic agent that damages the immune cells cannot cause the immune system to improve and correct immune deficiencies – rather than achieving the opposite – further aggravating this condition.
  5. Over the past two decades the AIDS epidemic has become a multibillion Rand market for the pharmaceutical investment industry with ARVs being essentially supplied from three drug exporting countries, the US , the UK and Germany .
  6. The continued growth and expansion of the global ARV market is essentially achieved by responding to the epidemic of immune deficiencies with the promotion of chemotherapeutic drugs – ARVs – that aggravate immune deficiencies. Through this marketing strategy, existing markets for ARVs and other drugs are being continuously expanded and markets for newly generated diseases are constantly being created.
  7. This aggressive marketing strategy exposes patients taking ARV drugs to compromise their immune systems and becoming susceptible to tuberculosis and other bacterial, viral and fungal disease. Even leprosy increases among patients taking ARV drugs, a fact that has not only alerted the scientific community, but the public at large as documented by a recent article in the “New York Times” (Annexure ‘ARV Leprosy NYT’).
  8. Particularly alarming are the toxic side effects of so-called highly active anti-retroviral treatments (HAART) which have been accompanied by an increase in deaths attributable to cancer, especially lung cancer (Annexure ‘AIDS 2003 HAART’). For more detailed information about the adverse effects of ARVs I refer the honourable Court to the affidavit of the sixth Respondent.
  9. The accusation that the pharmaceutical industry responds to diseases by promoting drugs that do not cure these diseases, rather than further aggravating them, is serious and is not made easily. One may even reject such a serious accusation for the simple fact that it violates all ethical standards as well as national and international laws. Fact is, however, that such marketing schemes by the pharmaceutical industry are widely used and are in no way limited only to ARV drugs and the AIDS epidemic.
  10. For more than a half a century chemotherapeutic agents have been promoted by drug companies as a “treatment of choice” in the fight against cancer. The ineffectiveness of chemotherapy in the global fight against cancer is evidenced by the fact that until today cancer has remained the third leading cause of death in the industrialized world. While this failure has been highly publicized, the reasons for it have not. Hardly anyone knows that many chemotherapeutic agents promoted by drug companies as cancer “treatments” are actually well-established “human carcinogens”, as documented by the Merck Manual and the official US-“Report on Carcinogens.” These carcinogens include such widespread cancer agents as Cyclophasphamide, Tamoxifen, Melphalan and others. (Annexure ‘Carcinogens Report’).
  11. The pharmaceutical marketing scheme to sell drugs that are known to cause cancer to millions of cancer patients –, and to promote drugs that are known to damage the immune system of millions of AIDS patients – is rather daring. This marketing scheme only works under one condition: that both cancer and AIDS are being upheld as “untreatable” and essentially “death verdicts.”
  12. This sobering scientific analysis has far-reaching economic consequences. Should those millions of patients affected by cancer or those affected by AIDS ever learn that science-based and safe health approaches are available to effectively help control these diseases, the global market of chemotherapeutic drugs will inevitably collapse.